Navigation Links
Alseres Pharmaceuticals to Host 2008 First Quarter Conference Call
Date:5/9/2008

ir. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia. The Company's lead molecular imaging product candidate is Altropane which is in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes including Parkinson's disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston.

Forward-Looking Statements

The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements include statements regarding Alseres' future expectations, beliefs, intentions, goals, strategies, plans or prospects regarding the future, including the development and commercialization of Altropane and Cethrin, the prospects of the Company's CNS and regenerative therapeutics programs, the Company's strategies to develop and commercialize axon regeneration technologies and the breadth of the Company's technologies and intellectual property portfolio. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the Company's Annual Report on Form 10-K for the year ended December 31, 2007 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Alseres from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any fut
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Alseres Pharmaceuticals, Inc. to Present at The Neurotech Industry Investing & Partnering Conference
2. Alseres Pharmaceuticals, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K
3. Alseres Pharmaceuticals, Inc. Raises $5 Million
4. Alseres Pharmaceuticals, Inc. to Present at New York Society of Security Analysts Conference
5. Vion Pharmaceuticals to Appeal Nasdaq Delisting
6. Amneal Pharmaceuticals Receives US FDA Approval for Three Generic Prescription Drugs; Two Using New FDA Electronic Filing Format
7. ISTA Pharmaceuticals to Present at the Bank of America 2008 Health Care Conference
8. ADVENTRX Pharmaceuticals to Report First Quarter 2008 Results
9. BioCryst Pharmaceuticals to Announce First Quarter 2008 Financial Results on May 8, 2008
10. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology Meeting
11. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter Financial Results and Provide a Clinical Program Update on May 6, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... HealthDay Reporter , THURSDAY, Sept. 18, 2014 (HealthDay ... patients seeking care at larger urban hospitals are likely to ... at smaller or more rural facilities, new research suggests. ... emergency care varies dramatically across hospitals in the United States," ... Renee Hsia, an associate professor at the University of California, ...
(Date:9/18/2014)... Chest Physicians (CHEST) together with the Chinese Thoracic ... of CTS that CHEST World Congress 2016 will ... critical care, and sleep medicine from around the ... slated for spring 2016. , CHEST World ... hands-on simulation training, keynote addresses, presentations by leading ...
(Date:9/18/2014)... September 18, 2014 Qualis Health, one ... published a white paper, “Advancing Primary Care through ... Information Technology.” , Authors Jeff Hummel, MD, MPH ... guidance to organizations engaged in the work of becoming ... IT can bolster PCMH objectives, such as generating and ...
(Date:9/18/2014)... have developed a new method to study Ebola virus ... Wildlife Conservation Society (WCS)-led research, published today in the ... use of fecal samples from wild great apes to ... virus. This represents a new tool for performing large, ... Ebola virus is studied and improve our understanding of ...
(Date:9/18/2014)... elderly men should not be routinely screened for prostate ... new study led by researchers at Henry Ford Hospital., ... JAMA Internal Medicine , focused on the use ... prostate cancer., "We found that the effect of the ... in particular has been minimal at best," says Jesse ...
Breaking Medicine News(10 mins):Health News:ER Waiting Times Vary Significantly, Studies Find 2Health News:ER Waiting Times Vary Significantly, Studies Find 3Health News:CHEST announces China as site of CHEST World Congress 2016 2Health News:Advancing Primary Care Through PCMH and HIT: New White Paper Connects the Dots 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 3Health News:Professional recommendations against routine prostate cancer screening have little effect 2
... small number of teenagers, including non-smokers, are misusing nicotine patches ... could be setting themselves up for health trouble if they ... time or if they use the products to maintain their ... says the students may have lied on the survey. And ...
... to Russian universities has picked up after a six ... Medical Council Act in March 2002. ,This was evident ... universities jointly organized by the Russian Cultural Centre and ... to the organisers, at least 235 students had applied ...
... lower the risk of pre-eclampsia, doctors say. ,Their review ... women can reduce the risk of perinatal death and ... pre-eclampsia or who had chronic hypertension, diabetes or renal ... to 150 mg) //of aspirin were less likely to ...
... to be a better treatment than the antiplatelet drug ... to new research in this week’s issue of the ... black men and women who recently had strokes that ... to blockage of a blood vessel in the brain. ...
... kidney transplant patients reduce their risk of heart attacks, ... been shown to minimize cardiovascular disease in people with ... people with normal cholesterol levels who have other conditions ... Kidney transplant patients have a significantly //higher risk of ...
... who grow slowly in their first year of life ... true regardless of the socioeconomic status of the child's ... by hampered brain development. Biological processes linked to poor ... function with consequent lower //occupational status and income. ...
Cached Medicine News:Health News:Teens Misusing Nicotine-Replacement Products 2Health News:Admission to Russian varsities is looking up 2
(Date:9/18/2014)... , Sept. 18, 2014  Decision Resources Group finds ... growth factor (VEGF) agent for wet AMD, is equally ... plans as Genentech,s Lucentis, which is the standard of ... care organization (MCO) directors do not identify a clear ... more likely than Lucentis to be listed on tier ...
(Date:9/18/2014)... 18, 2014  A $3 million grant from The ... of Michigan to establish a national center of excellence ... for Aging Research at U-M will focus on exploiting ... the effects of aging and postpone diseases in animal ... can help develop medications that may help people live ...
(Date:9/18/2014)... 2014  Halozyme Therapeutics, Inc. (NASDAQ: ... and Drug Administration (FDA) has removed the clinical ... in SWOG,s ongoing Phase 1b/2 clinical trial (S1313). ... drug PEGPH20 (PEGylated Recombinant Human Hyaluronidase) in combination ... metastatic pancreatic adenocarcinoma.  The study will resume under ...
Breaking Medicine Technology:Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 2Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 3$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 2$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 2SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 4
... Counter allows the user to quickly and accurately ... for digital counting or manual counting. An optional ... increasing magnification to 3.0X. The adjustable focusing rod ... or lowered. The lens also rotates a full ...
The Accucount 2000 is designed to automatically count microscopic objects in a field displaying totals on a highly visible digital readout....
... is a Accelerated Bacterial Enumeration System. Bacterial ... of colonies found by the volume dispensed ... A logarithmically decreasing volume of sample is ... Petri dish in an Archimedes spiral. The ...
... CEQ 8000 is a fully automated ... the capillary array with a patented linear ... sample, applies the voltage program, and analyzes ... review data quality and even customize automated ...
Medicine Products: